Mafosfamide Sodium Salt (CAS 84211-05-2)
See product citations (27)
QUICK LINKS
Mafosfamide Sodium Salt, an analog of cyclophosphamide, functions primarily through its capacity to induce apoptosis in lymphoblastoid cells, showcasing its pivotal role in the study of cellular death mechanisms. This compound′s action is rooted in its ability to intercalate into DNA, leading to the disruption of normal cellular replication and transcription processes, which are essential for cell survival and proliferation. As a consequence, Mafosfamide Sodium Salt serves as a tool in oncological research, particularly in understanding the intricacies of tumor cell behavior and the identification of potential targets for cancer therapy. Its efficacy as an antitumor agent in vitro further emphasizes its significance in the exploration of novel strategies for combating malignancies at the cellular level, offering insights into the molecular pathways that can be manipulated to hinder tumor growth and proliferation.
Mafosfamide Sodium Salt (CAS 84211-05-2) References
- Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution. | Gorin, NC., et al. 1999. Exp Hematol. 27: 1822-30. PMID: 10641600
- Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. | Goldstein, M., et al. 2008. Toxicol Appl Pharmacol. 229: 20-32. PMID: 18289623
- CD62L as a therapeutic target in chronic lymphocytic leukemia. | Burgess, M., et al. 2013. Clin Cancer Res. 19: 5675-85. PMID: 23948971
- Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. | Kikuchi, K., et al. 2014. PLoS Genet. 10: e1004107. PMID: 24453992
- DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. | Klaus, CR., et al. 2014. J Pharmacol Exp Ther. 350: 646-56. PMID: 24993360
- Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. | Knutson, SK., et al. 2014. PLoS One. 9: e111840. PMID: 25493630
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. | Ninomiya, S., et al. 2015. Blood. 125: 3905-16. PMID: 25940712
- Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557). | Douay, L., et al. 1989. Exp Hematol. 17: 429-32. PMID: 2653856
- Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557). | Kohn, FR. and Sladek, NE. 1987. Biochem Pharmacol. 36: 2805-11. PMID: 2820422
- The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. | Miller, CR., et al. 2017. Oncotarget. 8: 25942-25954. PMID: 28412730
- The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells. | Krajnak, S., et al. 2021. Anticancer Res. 41: 1243-1250. PMID: 33788715
- Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. | Douay, L., et al. 1995. Blood. 86: 2849-55. PMID: 7670119
- Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. | Skorski, T., et al. 1993. J Clin Invest. 92: 194-202. PMID: 8325984
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Mafosfamide Sodium Salt, 1 mg | sc-211761 | 1 mg | $413.00 | |||
Mafosfamide Sodium Salt, 10 mg | sc-211761A | 10 mg | $2943.00 | |||
Mafosfamide Sodium Salt, 25 mg | sc-211761B | 25 mg | $7283.00 |